NASDAQ:CNCE - Concert Pharmaceuticals Stock Price, Forecast & News

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Concert Pharmaceuticals Inc (NASDAQ:CNCE) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.13. The biotechnology company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.35 million. Concert Pharmaceuticals had a negative return on equity of 55.06% and a negative net margin of 7,291.37%. View Concert Pharmaceuticals' Earnings History.

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Concert Pharmaceuticals.

7 brokers have issued 12 month price objectives for Concert Pharmaceuticals' stock. Their forecasts range from $8.00 to $30.00. On average, they expect Concert Pharmaceuticals' stock price to reach $17.71 in the next twelve months. This suggests a possible upside of 57.0% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.

News stories about CNCE stock have been trending positive this week, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Concert Pharmaceuticals.

Some companies that are related to Concert Pharmaceuticals include Zogenix (ZGNX), IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Rocket Pharmaceuticals (RCKT), Supernus Pharmaceuticals (SUPN), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), NextCure (NXTC), Myovant Sciences (MYOV), Opko Health (OPK) and Akebia Therapeutics (AKBA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Lexicon Pharmaceuticals (LXRX) and Cidara Therapeutics (CDTX).

Concert Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (7.27%), Bank of America Corp DE (6.05%), Ingalls & Snyder LLC (6.15%), Renaissance Technologies LLC (2.14%), State Street Corp (1.38%) and Prudential Financial Inc. (1.24%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, James V Cassella, Nancy Stuart, Peter Barton Hutt, Richard Aldrich and Thomas G Auchincloss. View Institutional Ownership Trends for Concert Pharmaceuticals.

CNCE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Russell Investments Group Ltd., Perceptive Advisors LLC, California Public Employees Retirement System, Acadian Asset Management LLC, Prudential Financial Inc., New York State Common Retirement Fund and UBS Group AG. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Bvf Partners L P/Il and Peter Barton Hutt. View Insider Buying and Selling for Concert Pharmaceuticals.

CNCE stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Alyeska Investment Group L.P., Jacobs Levy Equity Management Inc., Panagora Asset Management Inc., Alambic Investment Management L.P., Oxford Asset Management LLP, Renaissance Technologies LLC and AQR Capital Management LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, Richard Aldrich and Thomas G Auchincloss. View Insider Buying and Selling for Concert Pharmaceuticals.

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNCE stock can currently be purchased for approximately $11.28.

Concert Pharmaceuticals has a market capitalization of $333.66 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.

The official website for Concert Pharmaceuticals is http://www.concertpharma.com/.

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]